Reproductive Health News and Research RSS Feed - Reproductive Health News and Research

Kala Pharmaceuticals completes $22.5 million Series B financing

Kala Pharmaceuticals completes $22.5 million Series B financing

Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company's proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has completed a $22.5 million Series B financing. [More]
Men's health conditions may be influenced by exposure to testosterone in womb, says study

Men's health conditions may be influenced by exposure to testosterone in womb, says study

Men's susceptibility to serious health conditions may be influenced by low exposure to testosterone in the womb, new research suggests. [More]
Vivere-Winter Park recognizes 25th Annual National Infertility Awareness Week

Vivere-Winter Park recognizes 25th Annual National Infertility Awareness Week

Infertility is a disease affecting more than 7 million people across the U.S., according to the National Survey of Family Growth. That number represents 12 percent of women of childbearing age or one in eight couples. [More]

Scientists develop microbicide gel that prevents transmission of multiple STIs in vagina/rectum in animals

Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). [More]

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. [More]
Auxogyn signs exclusive license agreement with Merck Serono for Eeva Test

Auxogyn signs exclusive license agreement with Merck Serono for Eeva Test

Auxogyn, Inc., a company dedicated to advancing women's reproductive health, today announced an exclusive license agreement with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany which operates as EMD Serono in the United States and Canada, for Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test. [More]
EMD Serono collaborates with Pfizer and Broad Institute

EMD Serono collaborates with Pfizer and Broad Institute

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. [More]
Bloomberg Philanthropies introduces multi-faceted $50M reproductive health program for women

Bloomberg Philanthropies introduces multi-faceted $50M reproductive health program for women

Bloomberg Philanthropies today announced the launch of a multi-faceted $50 million reproductive health program to prevent maternal deaths and help more women freely and safely make decisions about when to have children. [More]

Viewpoints: Be careful what you pray for; health law 'freakouts;' concerns about imported drugs

On Tuesday, the Supreme Court will consider a proposition that will strike many Americans as bizarre: that large, for-profit businesses can refuse on religious grounds to comply with a federal mandate that they include contraception in their employee health plans (3/25). [More]
Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012. [More]

WHO launches new guidance to help countries provide contraception information and services

In advance of International Women's Day on 8 March 2014, WHO is launching new guidance to help countries ensure human rights are respected in providing more girls, women, and couples with the information and services they need to avoid unwanted pregnancies. [More]
Novel HIV prevention products for women demonstrate safety in clinical studies

Novel HIV prevention products for women demonstrate safety in clinical studies

Two early clinical studies of novel HIV prevention products for women - the first combination antiretroviral (ARV) vaginal ring and a vaginal film - show the products to be safe and open the door to product improvements that could expand options for women-initiated prevention tools. The results of both studies were presented today at the 21st Conference on Retroviruses and Opportunistic Infections. [More]
Women using DMPA injection more likely to acquire HIV than women using NET-EN

Women using DMPA injection more likely to acquire HIV than women using NET-EN

Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston. [More]

FDA clears First Response Gold Digital Pregnancy Test

Church & Dwight Co., Inc. announced today that the U.S. Food and Drug Administration has cleared the First Response Gold Digital Pregnancy Test to determine if a woman is pregnant up to six (6) days before her missed period and with over 99% accuracy from the day of her expected period – a significant step in pregnancy test innovation. [More]

New research reveals link between BMI and amount of bacteria colonizing noses

Do attractive traits tell us anything about a person's reproductive health? New research in the American Journal of Human Biology reveals a link between Body Mass Index (BMI) and the amount of bacteria colonizing noses. [More]
Natera initiates distribution partnership with ProPath for Panorama non-invasive prenatal screening test

Natera initiates distribution partnership with ProPath for Panorama non-invasive prenatal screening test

Natera, a leading innovator in prenatal genetic testing, today announced the initiation of a distribution partnership with ProPath, a wholly physician-owned provider of pathology services to clinicians and medical facilities in the United States, for its Panorama non-invasive prenatal screening test (NIPT). [More]
Study examines trends in fertility rates among girls with mental illness

Study examines trends in fertility rates among girls with mental illness

Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital. [More]

Population Council launches large new research program to benefit adolescent girls in Kenya

​The Population Council announced today the launch of a large new research program designed to benefit adolescent girls in Kenya. The initiative will provide girls with access to interventions in the health, wealth creation, education, and violence-prevention sectors. [More]
Women with schizophrenia twice as likely to experience pre-term birth and pregnancy complications

Women with schizophrenia twice as likely to experience pre-term birth and pregnancy complications

Women with schizophrenia are nearly twice as likely to experience pre-eclampsia, pre-term birth and other serious pregnancy and delivery complications as women without the condition, a landmark study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital has found. [More]

Market research report on prefilled syringe devices and products

Reportlinker.com announces that a new market research report is available in its catalogue: Prefilled Syringe Devices, Products, Markets and Forecasts> [More]